

Advanced Imaging for Breast Cancer: Magnetic Resonance Imaging

Tom Yankeelov

Ingram Associate Professor of Cancer Research

Departments of Radiology, Physics, Biomedical Engineering, Cancer Biology

Vanderbilt University Institute of Imaging Science

Vanderbilt University



7 August 2013



Motivation

How is treatment response currently monitored?


- RECIST = Response Evaluation Criteria in Solid Tumors
 - First published in 2000
 - Idea: develop a simple method to assess therapy response in tumors to
-

- Applied only on patients with measurable disease at baseline
 - Uses only anatomical CT and MRI for response assessment
-


- Sum of longest diameter (LD) for all target lesions is calculated

→ The change in baseline sum LD will be used to characterize response


Motivation




Pre-therapy



Pre-therapy




2 months post-therapy



2 months post-therapy

Motivation



	Baseline	Visit 2	Visit 3	Visit 4	Visit 5
T1:	24	25	28	32	48
<u>T2:</u>	<u>14</u>	<u>15</u>	<u>16</u>	<u>18</u>	<u>23</u>
SLD:	38	40	44	50	71
(% ch)		+5%	+16%	+32%	+89%

- Anatomic imaging is limited; morphologic changes are nonspecific, often occur long after molecular changes are apparent
- Need methods to report on changes on the underlying pathophysiology

Next ~20 minutes of Your Life

1. Imaging Biomarkers
2. MR-based methods

Imaging Biomarkers in Cancer

- Anatomical/physiological

- Tumor size
- Cellular density
- Metabolism (glucose, choline, ATP, pH)
- Oxygenation (hypoxia, pO_2)
- Vascular properties (blood flow, angiogenesis)

Well-suited for
MRI, CT, US

- Tumor-Host Interactions

- Inflammation
- Extracellular matrix changes + signaling

Well-suited for
Nuclear + Optical

- Molecular

- Cell surface receptor interactions
- Intracellular signaling pathways (e.g. caspase)
- Gene expression

- Things MRI cannot do especially well:

- 1) Targeted agents not well suited to MRI

→ Optical (pre-clinical) and nuclear techniques have >> sensitivity

- 2) Several questions regarding drug effects not addressable by MRI

- Why is this the case?

- Tissue has a “background” relaxation rate, $R_1 (= 1/T_1)$

- To detect an R_1 contrast agent, R_1 must increase significantly compared to noise level and background variations; say, +10%

- If native $R_1 \approx 1 \text{ sec}^{-1}$, then minimum detectable $\Delta R_1 \approx 0.10 \text{ sec}^{-1}$

→ $\Delta R_1 = \text{relaxivity} \cdot [\text{CA}]$

→ Relaxivity $\approx 4 \text{ sec}^{-1}\text{mM}^{-1}$ for Gd-DTPA

→ Minimum $[\text{CA}] = 25 \text{ } \mu\text{M}$ throughout ROI! (PET $\sim 10^{-6} \text{ } \mu\text{m}$)

(less if relaxivity higher, but still quite challenging)


Diffusion weighted MRI

Diffusion weighted MRI

- Water molecules wander about randomly in tissue (Brownian Motion)
- In a free solution, after a time t , molecules travel (on average) a distance L from where they started
- But in tissue, compartment effects may hinder movement = restricted diffusion


- Boundaries may reduce distance molecules travel when compared to free molecules

- Thus, the *Apparent Diffusion Coefficient* (ADC) is lowered




Diffusion weighted MRI


- ADC depends on cell volume fraction



- Increasing cell density; more cell membranes per unit distance to hinder diffusion → lower ADC
- Tumor cellularity may be monitored by DWI



Diffusion weighted MRI




→ Sensitivity = true positive rate = $\text{TP}/(\text{TP} + \text{FN})$

→ Specificity = true negative rate = $\text{TN}/(\text{FP} + \text{TN})$

Dynamic Contrast Enhanced MRI

DCE-MRI

- Serial acquisition of images before, after an injection of contrast agent (CA)
- As CA perfuses into tissue, the T_1 and T_2 values of tissue water decrease
- Each voxel yields a signal intensity time course
- By fitting data to model, extract parameters that report tissue characteristics




K^{trans} = transfer rate constant

v_e = extravascular extracellular volume fraction

v_b = blood volume fraction

DCE-MRI



ROC Analysis
Sensitivity = 0.81
Specificity = 0.75
AUC = 0.80

Combining DW-MRI & DCE-MRI data:

Sensitivity = 0.88
Specificity = 0.82
AUC = 0.86


RECIST

Sensitivity = 0.33
Specificity = 0.95
AUC = 0.65

Magnetization transfer MRI

Magnetization transfer MRI

- Exploits transfer of magnetization between protons bound in macromolecules and free water protons




- Image contrast depends upon:
 - 1) Concentration of macromolecules
 - 2) Transfer rate between macromolecular and free water protons

Magnetization transfer MRI

- How do we quantify this measurement?
Magnetization transfer ratio (MTR) maps

$$\text{MTR} = 1 - \frac{S_{sat}}{S_0}$$




Magnetization transfer MRI

pCR: $\Delta\text{MTR} = -14\%$

Partial responder: $\Delta\text{MTR} = -7\%$

Progressive disease: $\Delta\text{MTR} = +6\%$









Magnetization transfer MRI

- Working hypotheses:
 - 1) Increased cellularity → Increased macromolecular pool → Increase in the MTR
 - 2) With successful treatment, MTR will return to values closer to healthy tissue


Chemical exchange saturation transfer MRI

Chemical exchange saturation transfer MRI

- Exploits magnetization transfer *and* chemical exchange of protons between amide protons and free water protons



Chemical exchange saturation transfer MRI



Quantification:
$$APT_{asym} = \frac{S(-3.5\text{ppm}) - S(3.5\text{ppm})}{S_0}$$

- Image contrast depends upon:
 - 1) Concentration of amide protons
 - 2) Exchange rate between amide and free water protons

Chemical exchange saturation transfer MRI

Complete responder (pCR):


$$\Delta\text{APT}_{\text{residual}} = -27\%$$

Progressive disease:

$$\Delta\text{APT}_{\text{residual}} = +78\%$$

Pre-NAT

Post-1 cycle




- Working hypotheses:

- Backbones of proteins and peptides contain amides
- Proteins/peptides concentrations altered in the tumor environment
- Changes in APT_{asym} corresponding to molecular changes in tumor

PET-MRI of breast cancer

<i>blood perfusion and permeability</i>
<i>extravascular extracellular volume fraction</i>
<i>plasma volume fraction</i>
cellularity
FDG-PET (glucose metabolism)



Summary

- RECIST criteria are fundamentally limited
- While MRI is not well-suited to molecular approaches, it can offer many clinical relevant measurements
 - DW-MRI
 - DCE-MRI
 - MT-MRI
 - CEST-MRI
 - Hyperpolarized MRI/MRS (J. Kurhanewicz, K. Brindle)

Thank you very much for your time and attention.

thomas.yankeelov@vanderbilt.edu



Vanderbilt University Institute of Imaging Science

